Tharimmune Launches $1.74 Million Public Offering with Common Stocks and Warrants

Tharimmune’s Common Stocks and Warrants are Now Available for Purchase

Announcement

Tharimmune Inc. (Tharimmune and the company), a biotechnological company, a leader for therapies in inflammation and immunology, has revealed the price of its registered direct public offering with a few purchasers, under the statement of shelf registration of $1.74 million of the company’s securities. Further, the statement includes 974,241 warrants to obtain shares of common stock at the price of $1.66 per share and RD common warrants at $1.786 per unit composed of one share of RD pre-funded warrant or common stock and, RD common warrant purchased. Also, it includes 414,331 shares of common stock, par value $0.0001 per share, and 559,910 pre-funded warrants to obtain shares of common stock (the RD pre-funded warrants). It might be active under the terms of the securities purchase agreement (the RD SPA).

Placement, Investors, and Regulatory Details

The gross proceeds from this offering are around $1.74 million before deduction of placement agent fees and approximate offering expenses. Tharimmune plans to utilize the net proceeds of the offering for general corporate purposes and working capital. The President Street Global LLC is hired as the exclusive placement agent. The closing of the benefaction is said to be dated on or around 25th July 2025, subject to the relief of customary closing state. The regulatory detail mentioned that the RD offering previously filed with the U.S. Securities and Exchange Commission, which was effective from 24th March 2023. The accompanying prospectus and preliminary prospectus supplement are based on the terms of the public offering, which is filed with the SEC. A confirmed accompanying prospectus and prospectus supplement to the offering will be available at www.sec.gov, and will be filed with the SEC. After that, the copies of both the officials will be accessible upon connecting to the President Street Global, LLC.

Before initiating any investment, the investors should compulsorily go through the accompanying prospectus and preliminary prospectus supplement, also information in addition should be read. The final terms of the benefaction will be revealed in a final prospectus supplement filed with the SEC. The RD offering that sold RD common warrants was registered under section 4 (a) (2) of the Securities Act of 1933, as amended, including Regulation D. Additionally, the RD common warrants and the primary shares are not registered under the state securities law or securities act. This will give investors informative insight into the terms and conditions of the public offering to help them invest wisely.